Haemonetics Corp. Company Profile (NYSE:HAE)

About Haemonetics Corp.

Haemonetics Corp. logoHaemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Supplies
  • Exchange: NYSE
  • Symbol: HAE
  • CUSIP: 40502410
Key Metrics:
  • Previous Close: $36.11
  • 50 Day Moving Average: $32.89
  • 200 Day Moving Average: $31.62
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 21.58
  • P/E Growth: 2.45
  • Market Cap: $1.85B
  • Outstanding Shares: 51,297,000
  • Beta: 0.8
Additional Links:
Companies Related to Haemonetics Corp.:

Analyst Ratings

Consensus Ratings for Haemonetics Corp. (NYSE:HAE) (?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $34.40 (4.55% downside)

Analysts' Ratings History for Haemonetics Corp. (NYSE:HAE)
Show:
DateFirmActionRatingPrice TargetDetails
8/15/2016SidotiDowngradeBuy -> Neutral$39.00View Rating Details
8/3/2016Barrington ResearchDowngradeOutperform -> Market PerformView Rating Details
8/2/2016Jefferies GroupBoost Price TargetBuy$32.00 -> $40.00View Rating Details
8/2/2016Benchmark Co.Boost Price TargetHold$28.00 -> $32.00View Rating Details
5/16/2016Goldman Sachs Group Inc.UpgradeSell -> Neutral$29.00View Rating Details
5/15/2016BTIG ResearchReiterated RatingHoldView Rating Details
5/12/2016Morgan StanleyReiterated RatingHoldView Rating Details
2/2/2016William BlairReiterated RatingMarket PerformView Rating Details
11/23/2015Raymond James Financial Inc.DowngradeMarket Perform -> UnderperformView Rating Details
(Data available from 8/26/2014 forward)

Earnings

Earnings History for Haemonetics Corp. (NYSE:HAE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016        
8/1/2016Q117$0.28$0.25$205.41 million$210.00 millionViewListenView Earnings Details
5/2/2016Q416$0.46$0.37$245.08 million$243.20 millionViewListenView Earnings Details
2/1/2016Q316$0.46$0.48$237.37 million$233.40 millionViewListenView Earnings Details
11/4/2015Q216$0.40$0.44$226.50 million$219.70 millionViewListenView Earnings Details
7/27/2015Q116$0.33$0.35$215.62 million$213.40 millionViewListenView Earnings Details
4/27/2015Q415$0.52$0.47$239.20 million$226.50 millionViewListenView Earnings Details
1/29/2015Q315$0.15$0.53$235.45 million$231.80 millionViewListenView Earnings Details
11/3/2014Q215$0.46$0.47$229.90 million$227.60 millionViewListenView Earnings Details
7/30/2014Q115$0.36$0.38$215.85 million$224.49 millionViewListenView Earnings Details
4/28/2014Q414$0.58$0.46$244.87 million$241.00 millionViewListenView Earnings Details
1/27/2014Q314$0.61$0.61$243.71 million$242.10 millionViewListenView Earnings Details
10/28/2013Q214$0.57$0.66$239.51 million$235.80 millionViewListenView Earnings Details
7/29/2013Q1 2014$0.47$0.46$232.98 million$219.50 millionViewListenView Earnings Details
5/1/2013Q4 2013$0.46$0.48$249.33 million$249.90 millionViewListenView Earnings Details
1/30/2013Q3 2013$0.47$0.50$251.93 million$247.40 millionViewListenView Earnings Details
10/29/2012Q213$0.77$0.90$223.47 million$218.18 millionViewN/AView Earnings Details
8/1/2012$0.71$0.55ViewN/AView Earnings Details
4/30/2012$0.83$0.80ViewN/AView Earnings Details
1/30/2012$0.80$0.86ViewN/AView Earnings Details
10/31/2011$0.77$0.72ViewN/AView Earnings Details
8/1/2011$0.77$0.65ViewN/AView Earnings Details
5/2/2011$0.83$0.85ViewN/AView Earnings Details
1/31/2011$0.82$0.89ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Haemonetics Corp. (NYSE:HAE)
Current Year EPS Consensus Estimate: $1.45 EPS
Next Year EPS Consensus Estimate: $1.67 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.43$0.49$0.46
Q2 20163$0.25$0.33$0.29
Q3 20164$0.40$0.46$0.44
Q4 20164$0.48$0.57$0.54
Q1 20173$0.26$0.30$0.27
Q2 20173$0.29$0.34$0.32
Q3 20173$0.38$0.44$0.41
Q4 20173$0.37$0.43$0.41
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Haemonetics Corp. (NYSE:HAE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Haemonetics Corp. (NYSE:HAE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/17/2016Ronald MerrimanDirectorSell4,337$35.14$152,402.18View SEC Filing  
8/4/2016Christopher SimonCEOBuy60,000$35.00$2,100,000.00View SEC Filing  
10/26/2015Byron SelmanInsiderSell344$32.13$11,052.72View SEC Filing  
10/26/2015Christopher J LindopCFOSell436$32.13$14,008.68View SEC Filing  
10/26/2015Sandra JesseEVPSell778$32.13$24,997.14View SEC Filing  
10/26/2015Susan M HanlonVPSell497$32.13$15,968.61View SEC Filing  
9/15/2015Brian ConcannonCEOSell6,569$35.15$230,900.35View SEC Filing  
9/1/2015Brian ConcannonCEOSell4,765$35.63$169,776.95View SEC Filing  
8/20/2015Christopher J. LindopCFOSell4,902$38.49$188,677.98View SEC Filing  
8/17/2015Brian ConcannonCEOSell6,569$39.28$258,030.32View SEC Filing  
7/20/2015Christopher J LindopCFOSell4,902$39.09$191,619.18View SEC Filing  
7/15/2015Brian ConcannonCEOSell6,569$39.59$260,066.71View SEC Filing  
7/6/2015Peter M AllenInsiderSell30,494$40.19$1,225,553.86View SEC Filing  
7/2/2015Jonathan WhiteInsiderSell2,385$41.14$98,118.90View SEC Filing  
6/22/2015Christopher J LindopCFOSell4,902$42.51$208,384.02View SEC Filing  
6/15/2015Brian ConcannonCEOSell6,569$42.51$279,248.19View SEC Filing  
6/10/2015Susan M HanlonVPSell6,000$43.00$258,000.00View SEC Filing  
6/1/2015Brian ConcannonCEOSell4,765$41.39$197,223.35View SEC Filing  
5/20/2015Christopher J LindopCFOSell4,902$41.65$204,168.30View SEC Filing  
5/1/2015Brian ConcannonCEOSell4,765$40.74$194,126.10View SEC Filing  
4/20/2015Christopher J LindopCFOSell4,902$41.55$203,678.10View SEC Filing  
4/1/2015Brian ConcannonCEOSell4,765$44.51$212,090.15View SEC Filing  
3/27/2015Susan M HanlonVPSell7,000$43.46$304,220.00View SEC Filing  
3/20/2015Christopher J LindopCFOSell4,902$44.26$216,962.52View SEC Filing  
3/10/2015Susan Bartlett FooteDirectorSell11,328$43.84$496,619.52View SEC Filing  
3/5/2015Ronald G GelbmanDirectorSell7,707$44.76$344,965.32View SEC Filing  
3/4/2015Ronald MerrimanDirectorSell14,258$43.80$624,500.40View SEC Filing  
3/2/2015Brian ConcannonCEOSell4,765$44.41$211,613.65View SEC Filing  
2/18/2015Pedro P GranadilloDirectorSell11,328$43.45$492,201.60View SEC Filing  
2/2/2015Brian ConcannonCEOSell4,765$39.15$186,549.75View SEC Filing  
1/2/2015Brian ConcannonCEOSell4,765$37.20$177,258.00View SEC Filing  
12/1/2014Brian ConcannonCEOSell4,765$36.72$174,970.80View SEC Filing  
11/3/2014Brian ConcannonCEOSell4,765$35.86$170,872.90View SEC Filing  
10/13/2014Peter M AllenInsiderSell36,426$35.22$1,282,923.72View SEC Filing  
8/12/2014Ronald MerrimanDirectorSell13,602$35.76$486,407.52View SEC Filing  
8/1/2014Brian ConcannonCEOSell4,380$35.27$154,482.60View SEC Filing  
7/7/2014Pedro P GranadilloDirectorSell5,837$35.97$209,956.89View SEC Filing  
6/12/2014Ronald G GelbmanDirectorSell9,184$34.00$312,256.00View SEC Filing  
6/6/2014Pedro P GranadilloDirectorSell5,837$34.69$202,485.53View SEC Filing  
5/12/2014Susan Bartlett FooteDirectorSell9,184$33.16$304,541.44View SEC Filing  
5/7/2014Pedro GranadilloDirectorSell5,837$31.14$181,764.18View SEC Filing  
5/1/2014Brian ConcannonCEOSell4,600$30.01$138,046.00View SEC Filing  
4/28/2014Peter AllenInsiderSell30,000$30.70$921,000.00View SEC Filing  
4/7/2014Pedro GranadilloDirectorSell5,837$31.98$186,667.26View SEC Filing  
4/1/2014Brian ConcannonCEOSell4,600$32.71$150,466.00View SEC Filing  
3/6/2014Ronald GelbmanDirectorSell12,000$36.17$434,040.00View SEC Filing  
3/3/2014Brian ConcannonCEOSell4,600$36.36$167,256.00View SEC Filing  
2/18/2014Susan HanlonVPSell3,690$39.00$143,910.00View SEC Filing  
2/7/2014Jonathan WhiteInsiderSell1,880$38.66$72,680.80View SEC Filing  
2/3/2014Brian ConcannonCEOSell7,600$37.63$285,988.00View SEC Filing  
1/27/2014Susan HanlonVPSell3,206$38.37$123,014.22View SEC Filing  
1/10/2014Susan HanlonVPSell4,000$41.80$167,200.00View SEC Filing  
1/2/2014Brian ConcannonCEOSell7,600$41.58$316,008.00View SEC Filing  
12/16/2013Susan HanlonVPSell4,000$43.50$174,000.00View SEC Filing  
12/9/2013Susan HanlonVPSell3,138$43.07$135,153.66View SEC Filing  
12/2/2013Brian ConcannonCEOSell7,600$42.31$321,556.00View SEC Filing  
11/12/2013Michael KellyInsiderSell61,400$39.70$2,437,580.00View SEC Filing  
11/1/2013Brian ConcannonCEOSell7,600$39.96$303,696.00View SEC Filing  
10/14/2013Michael KellyInsiderSell1,400$40.41$56,574.00View SEC Filing  
9/13/2013Michael KellyInsiderSell1,400$40.36$56,504.00View SEC Filing  
9/3/2013Brian ConcannonCEOSell13,000$39.87$518,310.00View SEC Filing  
8/1/2013Brian ConcannonCEOSell13,000$42.24$549,120.00View SEC Filing  
7/12/2013Michael P KellyInsiderSell1,400$44.10$61,740.00View SEC Filing  
7/1/2013Brian ConcannonCEOSell13,000$41.87$544,310.00View SEC Filing  
6/18/2013Christopher J LindopCFOSell68,628$42.50$2,916,690.00View SEC Filing  
6/14/2013Michael P KellyInsiderSell1,400$42.17$59,038.00View SEC Filing  
6/3/2013Brian ConcannonCEOSell13,000$41.15$534,950.00View SEC Filing  
5/21/2013Christopher J LindopCFOSell42,882$42.00$1,801,044.00View SEC Filing  
5/14/2013Michael P KellyInsiderSell1,400$39.66$55,524.00View SEC Filing  
5/1/2013Brian ConcannonCEOSell13,000$38.66$502,580.00View SEC Filing  
12/3/2012Brian ConcannonCEOSell13,000$40.75$529,750.00View SEC Filing  
11/12/2012Pedro P GranadilloDirectorSell16,000$80.40$1,286,400.00View SEC Filing  
9/4/2012Brian ConcannonCEOSell6,500$73.68$478,920.00View SEC Filing  
9/4/2012Christopher J LindopCFOSell61,783$74.34$4,592,948.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Haemonetics Corp. (NYSE:HAE)
DateHeadline
News IconHaemonetics Corporation (HAE) – Product Pipeline Analysis, 2016 According to 2016 research report (NYSE:HAE)
www.medgadget.com - August 25 at 5:24 PM
mysmartrend.com logoHaemonetics Shares Up 21.9% Since SmarTrend's Buy Recommendation (HAE) (NYSE:HAE)
www.mysmartrend.com - August 19 at 8:19 AM
mysmartrend.com logoUptrend Call Working As Haemonetics Stock Rises 22.9% (HAE) (NYSE:HAE)
www.mysmartrend.com - August 11 at 5:36 PM
live-pr.com logo"Haemonetics Corporation (HAE) - Financial and Strategic SWOT Analysis Review" Published (NYSE:HAE)
www.live-pr.com - August 10 at 5:37 PM
finance.yahoo.com logo4:03 pm Haemonetics announces that President and CEO Christopher Simon has acquired 60k shares of its common stock at an average price of $35.00/share during the last 3 business days (NYSE:HAE)
finance.yahoo.com - August 8 at 5:33 PM
publicnow.com logoHaemonetics CEO Completes Open Market Share Purchase (NYSE:HAE)
www.publicnow.com - August 8 at 5:33 PM
capitalcube.com logoETF’s with exposure to Haemonetics Corp. : August 5, 2016 (NYSE:HAE)
www.capitalcube.com - August 5 at 5:31 PM
fidaily.com logoBarrington Research Downgrades Rating On Haemonetics Corporation Common (HAE) (NYSE:HAE)
www.fidaily.com - August 5 at 8:17 AM
capitalcube.com logoHaemonetics Corp. :HAE-US: Earnings Analysis: Q1, 2017 By the Numbers : August 4, 2016 (NYSE:HAE)
www.capitalcube.com - August 4 at 5:40 PM
finance.yahoo.com logoHaemonetics (HAE) Lags Q1 Earnings, Tops Sales Estimates (NYSE:HAE)
finance.yahoo.com - August 2 at 5:38 PM
twst.com logoHaemonetics Corporation: Haemonetics 1st Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website (NYSE:HAE)
www.twst.com - August 2 at 10:08 AM
reuters.com logoBRIEF-Haemonetics Corp Q1 adjusted earnings per share $0.25 (NYSE:HAE)
www.reuters.com - August 2 at 10:08 AM
seekingalpha.com logoHaemonetics (HAE) Christopher Simon on Q1 2017 Results - Earnings Call Transcript (NYSE:HAE)
seekingalpha.com - August 2 at 10:08 AM
rttnews.com logoHaemonetics Corp. (HAE) Broke Out To A 3-Month High After Q1 Report (NYSE:HAE)
www.rttnews.com - August 2 at 10:08 AM
finance.yahoo.com logoEdited Transcript of HAE earnings conference call or presentation 1-Aug-16 12:00pm GMT (NYSE:HAE)
finance.yahoo.com - August 2 at 10:08 AM
finance.yahoo.com logoStrength seen in Haemonetics (HAE): Stock Soars 10.5% (NYSE:HAE)
finance.yahoo.com - August 2 at 10:08 AM
biz.yahoo.com logoHaemonetics Corp Earnings Call scheduled for 8:00 am ET today (NYSE:HAE)
biz.yahoo.com - August 1 at 8:00 AM
biz.yahoo.com logoQ1 2017 Haemonetics Corp Earnings Release - 06:00 am ET (NYSE:HAE)
biz.yahoo.com - August 1 at 7:07 AM
publicnow.com logoHaemonetics Appoints Bill Burke CFO (NYSE:HAE)
www.publicnow.com - August 1 at 6:21 AM
publicnow.com logoHaemonetics 1st Quarter Fiscal 2017 Earnings Release Available on Investor Relations Website (NYSE:HAE)
www.publicnow.com - August 1 at 6:21 AM
sg.finance.yahoo.com logoHaemonetics reports 1Q loss (NYSE:HAE)
sg.finance.yahoo.com - August 1 at 6:16 AM
newsmaker.com.au logoU.S. Therapeutic Plasma Exchange (TPE) Market Analysis, Size, Share, Growth, Trends and Forecast To 2021 (NYSE:HAE)
www.newsmaker.com.au - July 29 at 12:31 PM
4-traders.com logoHAEMONETICS CORP : Submission of Matters to a Vote of Security Holders (form 8-K) (NYSE:HAE)
www.4-traders.com - July 27 at 5:37 PM
biz.yahoo.com logoHAEMONETICS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NYSE:HAE)
biz.yahoo.com - July 27 at 5:08 PM
capitalcube.com logoHaemonetics Corp. :HAE-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 (NYSE:HAE)
www.capitalcube.com - July 26 at 9:22 AM
openpr.com logoNew Research Report on Hemostasis Testing Systems Market, 2016-2026 (NYSE:HAE)
www.openpr.com - July 25 at 5:25 PM
finance.yahoo.com logoHaemonetics Sets Date for 1st Quarter Fiscal 2017 Earnings Release: August 1, 2016 (NYSE:HAE)
finance.yahoo.com - July 18 at 5:19 PM
finance.yahoo.com logoGlobal Blood Collection and Processing Supplie Industry (NYSE:HAE)
finance.yahoo.com - July 12 at 9:45 AM
News IconHemostasis Testing Systems Market size in terms of volume and value 2016-2026 (NYSE:HAE)
www.medgadget.com - July 7 at 5:26 PM
capitalcube.com logoHaemonetics Corp. – Value Analysis (NYSE:HAE) : July 5, 2016 (NYSE:HAE)
www.capitalcube.com - July 5 at 12:11 PM
capitalcube.com logoHaemonetics Corp. breached its 50 day moving average in a Bullish Manner : HAE-US : July 1, 2016 (NYSE:HAE)
www.capitalcube.com - July 1 at 8:16 AM
News IconGlobal medical aspirator market forecast to 2021 detailed in new research report (NYSE:HAE)
www.whatech.com - June 30 at 8:14 AM
News IconMedical aspirator market growth and its future prospects in a new 2016 research report (NYSE:HAE)
www.whatech.com - June 28 at 5:20 PM
News IconContractual Waiver of Subrogation Applied to Owner’s Non-Work Property (NYSE:HAE)
www.jdsupra.com - June 23 at 4:35 PM
capitalcube.com logoHaemonetics Corp. breached its 50 day moving average in a Bullish Manner : HAE-US : June 21, 2016 (NYSE:HAE)
www.capitalcube.com - June 21 at 8:15 AM
capitalcube.com logoETF’s with exposure to Haemonetics Corp. : June 20, 2016 (NYSE:HAE)
www.capitalcube.com - June 20 at 2:31 PM
openpr.com logoApheresis Market worth 2.5 Billion USD by 2020 (NYSE:HAE)
www.openpr.com - June 20 at 11:35 AM
4-traders.com logoHaemonetics : Sources Sought Notice - Maintenance Service Agreement for Haemonetics Units (NYSE:HAE)
www.4-traders.com - June 14 at 5:14 PM
finance.yahoo.com logoHAEMONETICS CORP Financials (NYSE:HAE)
finance.yahoo.com - June 7 at 1:04 PM
4-traders.com logoHAEMONETICS CORP : Change in Directors or Principal Officers (form 8-K) (NYSE:HAE)
www.4-traders.com - June 6 at 5:15 PM
biz.yahoo.com logoHAEMONETICS CORP Files SEC form 8-K, Change in Directors or Principal Officers (NYSE:HAE)
biz.yahoo.com - June 6 at 4:34 PM
biz.yahoo.com logoHAEMONETICS CORP Files SEC form 10-K, Annual Report (NYSE:HAE)
biz.yahoo.com - June 1 at 4:19 PM
finance.yahoo.com logoInvetech, Haemonetics, and Coramed Technologies Receive 2016 Good Design Award® for Development of the TEG® 6s (NYSE:HAE)
finance.yahoo.com - June 1 at 8:00 AM
bilbaoya.com logoOracle Corporation (NYSE:ORCL) Updated Price Targets (NYSE:HAE)
bilbaoya.com - May 26 at 5:53 PM
publicnow.com logoQ1 2016: Sales growth 50% to EUR 67.94 million, EBIT-growth 100% to EUR 3.47 million,compared to prior year Q1 period (NYSE:HAE)
www.publicnow.com - May 26 at 8:57 AM
publicnow.com logoHaemonetics to Present at Jefferies 2016 Healthcare Conference (NYSE:HAE)
www.publicnow.com - May 26 at 8:17 AM
publicnow.com logo2015: Preliminary IFRS results (NYSE:HAE)
www.publicnow.com - May 26 at 6:47 AM
publicnow.com logoQ1 2016: Sales growth 50% to EUR 67.94 million, EBIT-growth 100% to EUR 3.47 million, compared to prior year Q1 period (NYSE:HAE)
www.publicnow.com - May 26 at 5:37 AM
News IconTech firms name new CEOs (NYSE:HAE)
www.bostonglobe.com - May 17 at 5:35 PM
bilbaoya.com logoHaemonetics Corporation (NYSE:HAE) Receives Neutral Rating From Goldman Sachs Analysts (NYSE:HAE)
bilbaoya.com - May 16 at 10:34 PM

Social

Haemonetics Corp. (NYSE:HAE) Chart for Friday, August, 26, 2016


Last Updated on 8/26/2016 by MarketBeat.com Staff